Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial

To investigate the effects of a single dose of 1.2 mg liraglutide, a once‐daily glucagon‐like peptide‐1 (GLP‐1) receptor agonist, on key renal variables in patients with type 2 diabetes.

[1]  M. Diamant,et al.  Acute renal haemodynamic effects of glucagon‐like peptide‐1 receptor agonist exenatide in healthy overweight men , 2016, Diabetes, obesity & metabolism.

[2]  G. Umpierrez,et al.  Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial , 2015, Diabetes Care.

[3]  J. Holst,et al.  Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. , 2015, American journal of physiology. Renal physiology.

[4]  J. Holst,et al.  Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. , 2015, American journal of physiology. Endocrinology and metabolism.

[5]  P. Rossing,et al.  Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[6]  B. Zinman,et al.  Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes , 2014, Diabetes Care.

[7]  N. Buus,et al.  Reproducibility of MRI renal artery blood flow and BOLD measurements in patients with chronic kidney disease and healthy controls , 2014, Journal of magnetic resonance imaging : JMRI.

[8]  J. Skov,et al.  Effects of GLP-1 in the Kidney , 2014, Reviews in Endocrine and Metabolic Disorders.

[9]  Yuichiro Yamada,et al.  The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. , 2014, Kidney international.

[10]  L. Bardram,et al.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. , 2014, Endocrinology.

[11]  J. Holst,et al.  Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males , 2014, Endocrine connections.

[12]  F. Persson,et al.  Tissue Renin–Angiotensin Systems: A Unifying Hypothesis of Metabolic Disease , 2014, Front. Endocrinol..

[13]  B. Kasiske,et al.  US Renal Data System 2013 Annual Data Report. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  R. Brook,et al.  Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. , 2014, American Journal of Hypertension.

[15]  Keiji Hirai,et al.  The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. , 2013, The Tohoku journal of experimental medicine.

[16]  T. Shibasaki,et al.  GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure , 2013, Nature Medicine.

[17]  J. Holst,et al.  Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. , 2013, The Journal of clinical endocrinology and metabolism.

[18]  S. Yamagishi,et al.  Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. , 2012, Microvascular research.

[19]  S. Nishikawa,et al.  Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes , 2012, Diabetes.

[20]  H. Yokomizo,et al.  GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. , 2012, Metabolism: clinical and experimental.

[21]  I. Macdonald,et al.  Investigation of the haemodynamic effects of exenatide in healthy male subjects. , 2012, British journal of clinical pharmacology.

[22]  S. Eiam‐Ong,et al.  Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre‐/post‐study , 2012, Internal medicine journal.

[23]  M. Christensen,et al.  Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[24]  A. Ingsathit,et al.  Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis , 2011, Diabetologia.

[25]  L. M. Lessa,et al.  Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. , 2011, American journal of physiology. Renal physiology.

[26]  D. de Zeeuw,et al.  Need for better diabetes treatment for improved renal outcome. , 2011, Kidney international. Supplement.

[27]  M. Zdravkovic,et al.  Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase , 2010, Drug Metabolism and Disposition.

[28]  A. Girardi,et al.  Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. , 2009, American journal of physiology. Renal physiology.

[29]  A. Nishiyama,et al.  Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. , 2009, Biochemical and biophysical research communications.

[30]  A. Zinsmeister,et al.  Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[31]  H. Kobori,et al.  Novel sandwich ELISA for human angiotensinogen. , 2007, American journal of physiology. Renal physiology.

[32]  J. Reubi,et al.  GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting , 2007, Journal of Nuclear Medicine.

[33]  A. Huber,et al.  Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. , 2004, The Journal of clinical endocrinology and metabolism.

[34]  J. Sturis,et al.  Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. , 2002, Diabetes care.

[35]  R. Roman,et al.  Renal effects of glucagon-like peptide in rats. , 2002, European journal of pharmacology.

[36]  J. Biederer,et al.  Quantitation of renal perfusion using arterial spin labeling with FAIR-UFLARE. , 2000, Magnetic resonance imaging.

[37]  S. Akabane,et al.  A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans. , 1990, Japanese journal of pharmacology.

[38]  K. Thomsen.  Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. , 1984, Nephron.

[39]  A. Kappelgaard,et al.  Measurement of angiotensin II in human plasma: technical modifications and practical experience. , 1976, Clinica chimica acta; international journal of clinical chemistry.

[40]  J. Bröchner-Mortensen.  A simple method for the determination of glomerular filtration rate. , 1972, Scandinavian journal of clinical and laboratory investigation.